



U. Linke

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)


(51) International Patent Classification: ⁷ C07C 311/47, 311/19, C07D 233/50, 333/50, 333/38, 213/75, 213/40, 235/30, A61K 31/215, 31/415, 31/38, 31/44		A3	(11) International Publication Number: WO 00/41469 not
(21) International Application Number: KB-RP PCT/EP00/00120 Patente & Lizenzen		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 11 January 2000 (11.01.00) 24. Nov. 2000		(43) International Publication Date: 20 July 2000 (20.07.00)	
(30) Priority Data: 09/232,738 15 January 1999 (15.01.99) EINGANG BAYER AG LEVERKUSEN			
(71) Applicant (for all designated States except US): BAYER AKTIENGESELLSCHAFT [DE/DE]; D-51368 Leverkusen (DE).			
(72) Inventors; and (75) Inventors/Applicants (for US only): SCHOOP, Andreas [DE/DE]; Stefan 3, D-51491 Overath (DE); MÜLLER, Gerhard [DE/DE]; Berliner Strasse 70, D-51977 Leverkusen (DE); BRÜGGEMEIER, Ulf [DE/DE]; Leysiefen 20, D-42799 Leichlingen (DE); VISMIDT, Delf [DE/DE]; Am Eckbusch 55b, D-42113 Wuppertal (DE); STELTE-LUDWIG, Beatrix [DE/DE]; Götzeide 10f, D-42489 Wülfrath (DE); WELDENICH, Jory [DE/DE]; Damschkeweg 49, D-42113 Wuppertal (DE); VALBERS, Markus [DE/DE]; Edlerather Weg 154, D-51375 Leverkusen (DE).			
(74) Common Representative: BAYER AKTIENGESELLSCHAFT; D-51368 Leverkusen (DE).			
(54) Title: β -PHENYLALANINE DERIVATIVES AS INTEGRIN ANTAGONISTS			

Published

With international search report.

(88) Date of publication of the international search report:

16 November 2000 (16.11.00)



(1)

(57) Abstract

The present invention relates to compounds of general formula (1), wherein R^4 is $-\text{SO}_2R^4$, $-\text{COOR}^4$, $-\text{COR}^4$, $-\text{CONR}^4_2$ or $-\text{CSNR}^4_2$; R^4 is hydrogen, a substituted or unsubstituted alkyl or cycloalkyl residue, a substituted or unsubstituted aryl residue or a saturated or unsaturated, optionally substituted heterocyclic residue; R^6 is a substituted or unsubstituted alkyl or cycloalkyl residue, a substituted or unsubstituted aryl residue or a saturated or unsaturated, optionally substituted heterocyclic residue; L is a sulphonamide, amide, ether, ester, keto, urea, thioether, sulphoxide or sulphone unit optionally extended by one or two methylene groups; and X is N, O or S; and their physiologically acceptable salts and stereoisomers. The present invention furthermore relates to a process for the preparation of the compounds of formula (1), a pharmaceutical composition containing at least one of these compounds, and the use of compounds of formula (1) for the production of a pharmaceutical composition having integrin-antagonistic action and in particular for the inhibition of angiogenesis and/or for the therapy and prophylaxis of cancer, osteolytic diseases such as osteoporosis, arteriosclerosis, restenosis and ophthalmic disorders.

4A 33 364

*